Daiichi goes to bond market for refinancing

Daiichi Sankyo, Japan's third-largest drugmaker, plans to sell as much as $3.12 billion in bonds to refinance a loan taken for its $5 billion acquisition of Ranbaxy Laboratories. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.